As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.
13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 260 260 |
26%
26%
|
|
| Gross Profit | 233 233 |
31%
31%
|
|
| EBITDA | 88 88 |
369%
369%
|
|
| EBIT (Operating Income) EBIT | 69 69 |
230%
230%
|
|
| Net Profit | 61 61 |
220%
220%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
| Head office | Canada |
| CEO | Peter Greenleaf |
| Employees | 130 |
| Founded | 1993 |
| Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


